MedTrace Logo

Helicobacter Pylori Eradication With a New Sequential Treatment

NCT00132171 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2021-03-18

No results posted yet for this study

Summary

Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection.

Conditions

  • Helicobacter Pylori Infection
  • Non Ulcer Dyspepsia
  • Duodenal Ulcer
  • Gastric Ulcer
  • Chronic Active Gastritis
  • Gastritis

Interventions

DRUG

Sequential therapy

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Principal Investigators

  • Angelo Zullo, MD · Nuovo Regina Margherita Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Completion
2001-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132171 on ClinicalTrials.gov